Validation Study of the EMILY AI Device in Acute and Chronic Respiratory Failure

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAether Tech S.L.

About this trial

Currently, there is no holistic solution for patients with respiratory diseases that includes oxygenation and management of a patient with respiratory disease, combining dynamic and automatic O2 administration and the detection of clinical worsening, generating a diagnostic suspicion, a management proposal, and notifying the medical team.

For device validation, prospective studies will be conducted in patients in respiratory intermediate care units, conventional hospitalization, during physical activity in the hospital setting, and in an out-of-hospital setting. The device will be evaluated in terms of oxygenation efficacy, response time, patient safety, efficiency, versatility, clinical benefit, and adaptability.

Eligibility criteria

Qualifiers

Men and women over 18 years of age.

Admitted to intermediate respiratory care unit with a diagnosis of acute respiratory failure for at least 8 hours.

Informed consent understood and signed.

Disqualifiers

Hemodynamic instability.

Severe temperature changes.

Hemoglobinopathies, severe anemia, severe acidosis, or severe alkalosis.

Anatomical disturbances.

Trial design

Treatments tested in this trial

  • Emily.AI

Treatment groups

20 Participants
are divided into 1 treatment group

Sponsors and collaborators

Aether Tech S.L.

Lead sponsor

Hospital Universitario Fundación Jiménez Díaz

Collaborator

Hospital Clinic of Barcelona

Collaborator